A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.

Trial Details

NCT ID
NCT07207395
Phase
PHASE2
Sponsor
The Christ Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • JBI-802
  • Pembrolizumab
Locations (sample)
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • Males or females aged ≥18 years at Screening.
  • Participants with a histologically confirmed diagnosis of locally advanced or metastatic NSCLC harboring an STK11 mutation.
  • Screening laboratory values:
  • Absolute neutrophil count (ANC) ≥1500 cells/mm3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →